Improved retroviral suicide gene transfer in colon cancer cell lines after cell synchronization with methotrexate by Finzi, Laetitia et al.
RESEARCH Open Access
Improved retroviral suicide gene transfer in colon
cancer cell lines after cell synchronization with
methotrexate
Laetitia Finzi
1, Aurore Kraemer
1,2, Claude Capron
3, Severine Noullet
1, Diane Goere
1, Christophe Penna
1,
Bernard Nordlinger
1, Josette Legagneux
4, Jean-Fançois Emile
2 and Robert Malafosse
1,2*
Abstract
Background: Cancer gene therapy by retroviral vectors is mainly limited by the level of transduction. Retroviral
gene transfer requires target cell division. Cell synchronization, obtained by drugs inducing a reversible inhibition
of DNA synthesis, could therefore be proposed to precondition target cells to retroviral gene transfer. We tested
whether drug-mediated cell synchronization could enhance the transfer efficiency of a retroviral-mediated gene
encoding herpes simplex virus thymidine kinase (HSV-tk) in two colon cancer cell lines, DHDK12 and HT29.
Methods: Synchronization was induced by methotrexate (MTX), aracytin (ara-C) or aphidicolin. Gene transfer
efficiency was assessed by the level of HSV-TK expression. Transduced cells were driven by ganciclovir (GCV)
towards apoptosis that was assessed using annexin V labeling by quantitative flow cytometry.
Results: DHDK12 and HT29 cells were synchronized in S phase with MTX but not ara-C or aphidicolin. In
synchronized DHDK12 and HT29 cells, the HSV-TK transduction rates were 2 and 1.5-fold higher than those
obtained in control cells, respectively. Furthermore, the rate of apoptosis was increased two-fold in MTX-treated
DHDK12 cells after treatment with GCV.
Conclusions: Our findings indicate that MTX-mediated synchronization of target cells allowed a significant
improvement of retroviral HSV-tk gene transfer, resulting in an increased cell apoptosis in response to GCV.
Pharmacological control of cell cycle may thus be a useful strategy to optimize the efficiency of retroviral-mediated
cancer gene therapy.
Background
Cancer gene therapy by suicide gene transfer remains an
alternative approach to increase selectivity in cancer
treatment [1]. The enzyme prodrug strategy, involving
transfer of the suicide gene, i.e. HSV-tk,t ot u m o rc e l l s
followed by ganciclovir (GCV) treatment, is the most
widely used [2-5]. HSV-TK phosphorylates GCV to its
monophosphate form that is then converted by cellular
kinases into GCV triphosphate, which causes DNA
chain termination and cell death [6]. In vivo,t h i ss t r a t -
egy involves both a direct cytotoxic effect and a bystan-
der effect [7]. The bystander effect confers cytotoxicity
to the neighboring nontransduced cells [8], and a distant
anti-tumor immune response. These aforementioned
ways for killing tumors are related to the quantitative
efficiency of gene transfer [9,10]. However, one of the
major obstacles to successful cancer gene therapy is the
inadequate transduction of the target cells [11]. In vivo,
several studies have shown that the number of cells
transduced by retroviral vectors constitutes less than
10% of the target cell population [12,13].
The transduction efficiency of defective murine-
derived retroviral vectors requires target cells to be in
division because integration of the great size viral DNA-
protein complex needs the metaphasic breakdown of the
nuclear membrane. Integration of the transgene thus
depends on the phase of the cycle where the target cells
are [14-16]. Consistently, the relationship between cell
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shown [15,17,18]. The gene transfer efficiency was lower
in cultured cells enriched in G0-G1 phase than that in
similar cell populations enriched in S, G2 and M phases
[18]. The accumulation of cells blocked in a determined
cell cycle phase which is the definition of synchroniza-
tion, could thus improve the efficiency of gene transfer
and finally the effectiveness of viral transduction. Con-
sistently, cells need to be synchronized in S phase due
to the intracellular half-life of murine retroviruses. Syn-
chronization of cells in S phase can be obtained in vitro
by serum starvation or by drugs inducing a reversible
DNA synthesis inhibition. Methotrexate (MTX), aphidi-
colin or aracytin (ara-C) have been used to synchronize
several cell lines in S phase. The effect of these drugs is
reversible in respect with the micromolar concentrations
used [19-22]. Although synchronization has been used
for improving the efficacy of chemotherapy [23,24], the
effect of synchronization on the efficiency of retroviral
gene transfer has never been evaluated in colon cancer
cells. The aim of this study was to evaluate whether
transduction efficiency may be increased by the synchro-
nization of target cells before retroviral gene transfer.
Methods
Cell culture
We used two colon cancer cell lines: the human HT29
and the murine DHDK12 pro-b (Pr. Martin, Dijon;
France) cell lines. Cell lines were cultured in DMEM
medium containing 10% calf serum/penicillin (50 units/
ml)/streptomycin (50 μg/ml) at 37°C in 5% CO2.W e
used retroviral vectors carrying Escherichia-coli b-galac-
tosidase (b-gal) [25] and herpes simplex thymidine
kinase (HSV-tk) genes associated with pac and neoR
gene respectively as positive selectable marker genes.
Amphotropic packaging cells were generated from the
human embryonic kidney cell line 293. The packaging
cells stably express Friend Murine Leukemia Virus (F-
MuLV) strain FB29 gag/pol genes and an amphotropic
envelop gene derived from pPAM3 (A.D Miller Seattle,
WA, USA). Packaging cells were transfected with plas-
mids pTG 5391 (FB29 LTR-lacZ-SV40-Puro-LTR, clone
E17-12 -TG 5391) or pTG 9344 (FB29 LTR-PGK-TK-
IRES-Neo -LTR clone E 17-21 pTG 9344) to isolate the
retroviral producer clone E17-12 -TG 5391 and E 17-21
TG 9344 (Transgene S.A., Strasbourg, France). The ret-
roviral producer clone were cultured in DMEM supple-
mented with 4.5 g/L of glucose, 1% non-essential amino
acids, 40 μg/ml gentamycin (Sigma) and 10% calf serum.
Culture supernatant was harvested, filtered through a
0.45 μm nitrocellulose filter (Sartorius, Goettingen, Ger-
many) and used in the presence of polybrene (Sigma) at
8 μg/ml final concentration. NIH 3T3 fibroblasts were
cultured in DMEM supplemented with 40 μg/ml
gentamycin and 10% heat inactivated NBBS (GIBCO/
BRL). Retroviral titration was determined by infecting
NIH 3T3 fibroblasts with serial dilutions of the culture
medium and staining respectively for b-galactosidase
activity with X-gal protocol [26] or for HSV-TK expres-
sion using monoclonal antibody anti-HSV-TK as
described below. All point titrations were performed
four times. The titer of viral preparation was 4.9 (± 1.2)
×1 0
6 focus-forming units (FFU/ml) for TG 9344 and
1.7 (± 0.9) × 10
7 FFU/ml for TG 5391. The absence of
competent replication helper retrovirus was checked by
NIH 3T3 mobilization assay
Treatment of cells with MTX, ara-c or aphidicolin
DHDK12 and HT29 cells were plated into 12 well plates
at 5.10
5 cells/well and treated with 0.08 μM methotrex-
ate (Wyeth-Lederle, Puteaux, France) or 0.075 μM1 - b-
D-arabinofuranosyl (Cytarabin-Pharmacia-Upjohn) or 25
μM aphidicolin (Sigma) for 24 hr. The concentrations of
the drugs used in our study were chosen according to
previously published studies [19,21,22]. Furthermore, we
determined the IC50 of these drugs by a growth curve
analysis. All concentrations used in our study were
lower than the calculated IC50 (Table 1). After treat-
ment, the drug-containing medium was removed; the
cells were washed twice with phosphate-buffered saline
( P B S )a n df r e s hm e d i u mw a sp r o v i d e d .E v e r y2t o6h r
during 72 hr, cell cycle distribution were obtained by
flow cytometric determination of the DNA content of
propidium-iodide (PI)-stained cells as described pre-
viously [27]. The cells were analyzed on a cytofluorom-
eter EPICS XL-MCL (Coulter Beckman, Miami, USA)
with an argon laser emitting at a wavelength of 488 nm.
The analysis of fluorescence was carried out starting
from an acquisition window determined by a two
dimensional histogram representing the structure of the
cells scaled to their size. This acquisition window was
then used to produce a histogram representing the
number of PI positive cells sorted by intensity of fluor-
escence, expressed in logarithmic curve mode.
Gene transfer into synchronized cells
DHDK12 and HT29 cells were transduced with the
reporter gene b-gal. After removal of drug-containing
medium, samples were taken every 8 hr during 72 hr.
For each time, cells were infected with 1 ml of 0.45 μm
Table 1 IC50 of Methotrexate, Ara-C and Aphidicolin in
DHDK12 and HT29 cell lines
IC 50 Methotrexate Ara-C Aphidicolin
DHDK12 cells 0.16 μM4 0 μM3 0 μM
HT29 cells 0.1 μM6 0 μM3 0 μM
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sence of 8 μg/ml of polybrene.
Then, HSV-tk gene was used during optimal period
determined with the reporter gene for each cell line.
During this period, cells were infected with 1 ml of 0.45
μm filtered TG 9344 packaging cells supernatant in the
presence of 8 μg/ml of polybrene at various time points
after MTX removal.
For each time point, appropriate controls were per-
formed. Transgene expression was determined 48 hr
after transduction.
Transgene expression assay
For detection of b-galactosidase activity, cells transduced
by TG 5391 were fixed for 15 min at 37°C with 0.5% of
glutaraldehyde, then washed two times with PBS and
stained with X-gal for cytochemical analysis, as pre-
viously described. The quantitative detection of b-gal
expression was performed with the fluorescein-di-b-D-
galactopyranoside (FDG) (Sigma) by flow cytometry
[28]. Cells were harvested (trypsin-EDTA), washed and
resuspended at a concentration of 5.10
5/ml in 25 μlo f
PBS containing 2% fetal calf serum, at 37°C for 10 min.
The b-galactosidase activity was obtained by cell incuba-
tion in 25 μl of 2 mM FDG solution for one min at 37°
C, then for one hour at 0°C, in 1 ml of PBS. The fluor-
escence was analyzed by flow cytometry. Non-trans-
duced cells formed the control group.
For HSV-TK expression analysis, cells transduced by
TG 9344, cultured on slides (Labtek II-Nunc), were
fixed for 15 min at 4°C with 4% paraformaldehyde and
incubated with PBS containing 0.2% serum bovine albu-
min (SAB) and 0.1% saponin for 5 min. Cells were incu-
bated with anti-HSV-TK mouse monoclonal antibody
4C8 (W. Summers, Yale University, USA) 1/50, for 30
min at room temperature. After washing in PBS, cells
were incubated for 10 min in a secondary antibody solu-
tion of goat anti-mouse coupled to biotin (LSAB 2 Sys-
tem Peroxydase, Dako). Cells were washed in PBS and
incubated 10 min with streptavidin-peroxydase. The
revelation was achieved by incubation for 5 min with 3-
3’ diaminobenzidine (DAB) leading to cytoplasmic
brown precipitates. Cells were counterstained with
hematoxylin.
For flow cytometry analysis, cells were harvested,
washed in PBS and fixed with 4% paraformaldehyde for
15 min at 4°C in PBS. Cells were washed in incubation
buffer (0.2% SAB, 0.1% saponin in PBS containing 0.2%
of sodium azide) then incubated in 200 μlo fa n t i - H S V -
TK monoclonal antibody 4C8, diluted to 1/50 in incuba-
tion buffer for 30 min at room temperature. Cells were
washed three times with PBS. The pellet was resus-
pended 30 min at room temperature, in 200 μlo fg o a t
anti-mouse antibody coupled to FITC, diluted to 1/100
in incubation buffer. Cells were washed and resuspended
in 1 ml of PBS for flow cytometry analysis.
Measurement of ganciclovir-induced cytotoxicity in
synchronized cells
Flow cytometry was carried out on synchronized cell,
transduced with TG 9344 at different periods, after 72
hr of 20 μM GCV treatment to quantitate cell apoptosis.
Apoptosis was determinate by staining cells with
annexin V-FITC and propidium-iodide (PI) labeling,
because annexin V can identify the externalization of
phosphatidylserine during the apoptotic progression and
therefore detect early apoptotic cells [29]. Cells were
transduced with TG 9344 vector, on 12-well plates and
treated after 24 hr by 20 μM GCV. Control cells were
no transduced or untreated. After 72 hr of treatment,
cells were harvested, and washed twice in PBS. The pel-
let was resuspended in 1 ml of 100 mM HEPES/NaOH,
pH 7.5. Then 500 μl of the cell suspension were incu-
bated in presence of 2 μg/ml annexin V-FITC, and 10 μl
of PI (100 μg/ml) for 10 min. Samples were immediately
analyzed by flow cytometry on a bi-parametric histo-
gram giving the level of annexin V-FITC and PI
fluorescence.
Apoptosis was assessed by DNA fragmentation assay.
Samples of 5.10
5 pTG 9344 transduced cells with or
without synchronization were treated 96 hr with 20 μM
GCV. Cells then were centrifuged at 800 g for 5 min at
4°C. The pellet was resuspended in 20 μl of lysis buffer
( E D T A2 0m M ,T r i s1 0 0m M ,S D S0 , 8 % ,p H8 ) .T h e n
10 μl of 500 UI/ml RNAse (Sigma) were added for 60
min at 37°C. The mix was incubated 90 min at 50°C
with 10 μl of 20 mg/ml proteinase K. Migration was
achieved on 1.8% agarose gel containing 0.5 μg/ml ethi-
dium bromide at 35 V during 4 hr. MSP I digested PBR
322 was used as a size marker. Non-transduced cells
treated with MTX or GCV constituted control groups.
Statistical analysis
Comparisons were made using the Student’stt e s t .P<
.05 was considered as significant.
Results
Altered progression in the cell cycle by methotrexate,
ara-C or aphidicolin
We first assessed the effect of drugs on DHDK12 and
HT29 cell cycles to delineate the time for which a maxi-
mum of cells were in S phase after drug removal.
The effects of the three drugs, i.e. MTX, ara-C and
aphidicolin, on the cell cycle were preliminary assessed
in DHDK12 cells. After a 24 hr treatment with MTX,
ara-C or aphidicolin, cells were analyzed between 0 and
72 hr after drug removal for DNA content by flow
cytometry.
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Page 3 of 12In the DHDK12 cell line, 20% of cells were in S phase
in the absence of drug and this rate was constant over
time (Figure 1A). When DHDK12 cells were treated
with ara-C or aphidicolin, 25% and 35% of cells were in
S phase 10 hr after ara-C or aphidicolin removal,
respectively (Additional file 1). By contrast, treatment
with MTX resulted in 51% of the cells to be in S phase,
while 28% were in G0-G1 phase, 10 hr after drug
removal (Figure 1A). The ratio of cells in S phase
remained higher than that in G1 phase up to 30 hr
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Figure 1 Distribution in cell cycle-phase after MTX treatment. Cell cycle phases of DHDK12 cells (A)a n dH T 2 9c e l l s( B) were obtained by
uniparametric flow cytometry analysis of DNA content (propidium iodide red-fluorescence intensity in fluorescence units) at various time after
MTX removal. On the ordinate is shown the number of cells corresponding to the fluorescence units.
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Page 4 of 12following MTX removal. This combination of an
increase of cells in S phase and a decrease of cells in G1
phase resulted in a wave of cells in G2-M between 10
and 24 hr after MTX removal. The synchronization of
cells in S phase by MTX was reversible as the pattern of
cell cycle progression of MTX-treated cells was similar
to that of untreated cells 48 hr after drug removal (Fig-
u r e1 A ) .O u rr e s u l t st h u ss u g g e s tt h a tM T Xi sm o r e
effective in synchronizing DHDK12 cells in S phase than
ara-C or aphidicolin. Consequently, the efficacy of MTX
in synchronizing cells in S phase was then tested in the
HT29 cell line.
In HT29 cell line, the effect of MTX on cell cycle pro-
gression was slightly different. As illustrated in Figure
1B, cells began to accumulate in S phase almost imme-
diately after MTX removal. While the rate of cells in S
phase was 18% without treatment (Figure 1B), this rate
reached 55% 6 hr after MTX removal and decreased
thereafter to reach the ratio of untreated cells 24 hr
after MTX removal.
Taken together, these observations indicate that the
pattern of cell cycle synchronization after MTX removal
is specific for each cell line. Because we hypothesize that
gene transfer efficiency is improved by potent cell cycle
synchronization, the time window for transduction
experiments with the b-gal reporter gene should be dif-
ferent between the two cell lines.
Improvement of gene transfer efficiency in synchronized
cell
To determinate the optimal period for gene transfer in
synchronized cells, we used the b-gal reporter gene. The
rate of DHDK12 cells transduced with the b-gal gene
was 3% with X-Gal staining while it was 10% with FDG
in flow cytometry (data not shown). The treatment of
DHDK12 cells with MTX improved retroviral gene
transfer efficiency. Figure 2 shows that the level of
transduction increased in cells synchronized in S phase.
The highest level of transduction was obtained in the
cells infected 20 hr after MTX removal. At that time,
the proportion of transduced cells was 26% for cells
treated with MTX, while it was 11% in untreated cells
(Figure 2A). In the MTX-treated cell population, 44% of
cells were in S phase. When the cell cycle distribution
of MTX-treated cells returned to the control value 54
hr after drug removal, the efficiency of transduction
became similar to that of control cells (Figure 2A).
Thus, the optimal period to improve transduction effi-
ciency of reporter gene in synchronized cells was
obtained between 12 and 32 hr after drug removal.
Similar experiments were performed in HT29 cells.
Accumulation of HT29 cells in S phase was observed
almost immediately after drug washout. Accordingly, the
highest transduction rate for b-gal gene was observed 6
hr after drug washout (Figure 2B). The efficiency of
transduction was comparable to the control cells 12 hr
after drug washout (Figure 2B).
As we first used the b-gal reporter gene to delineate
the optimal period for subsequent HSV-tk gene transfer
in synchronized cells, we focused our investigation for
the transfer of the suicide gene HSV-tk in a time win-
dow for which the highest level of transduction with the
b-gal reporter gene was obtained for each cell line.
DHDK12 cells thus were treated with MTX and trans-
duced with the HSV-tk gene from 12 to 32 hr after drug
removal. Irrespective of the time used for transduction
after MTX removal, the determination of the HSV-TK
p r o t e i ne x p r e s s i o nu s i n gflow cytometry or immunos-
taining was always performed 48 h after transduction to
ensure protein expression of the transgene. As illu-
strated in Figure 3, immunostaining using peroxydase
and DAB provided a brown intracellular precipitate in
HSV-TK transduced cells. The rate of fluorescent
untreated DHDK12 cells (control cells) expressing HSV-
TK as measured by flow cytometry was 15% (Figure
4A). As observed for the b-gal reporter gene, the highest
transduction rate in MTX-treated cells obtained after 20
hr of drug washout was 30% while it was 15% in control
cells (Figure 4A).
For HT29 cells, transduction efficiency with HSV-TK
was maximal at 6 hr after drug washout and reached
22% while it was 15% in untreated cells (Figure 4B).
Therefore according to the host cell cycle, we found
that pre-treatment with MTX resulted in improved gene
transfer efficiency in these two cells lines.
Enhancement of apoptosis in synchronized cell
To determine whether the improvement of HSV-tk gene
transfer efficiency by cell synchronization resulted into
an increased GCV-mediated cell death, we measured the
level of cell apoptosis after GCV treatment using
a n n e x i nV - F I T C .T h ep r e s e n c eo fa p o p t o s i so b s e r v e d
with annexin V labeling was confirmed by the DNA
fragmentation method (Figure 5). Annexin V labeling
was increased in MTX-treated DHDK12 and HT29 cells
transduced with HSV-tk gene and then treated for 72 hr
by GCV.
In non-transduced cells, 5% of MTX treated cells were
labeled for annexin V-FITC after treatment by GCV
(Figure 6A). This corresponds to the intrinsic toxicity of
MTX.
The percentage of MTX-treated DHDK12 cells under-
going apoptosis (Annexin V+, PI-) was two fold higher
after MTX withdrawal (46% vs. 23% in the untreated
cell population). The difference was maximal in cells
transduced 20 hr after MTX withdrawal (Figure 6B).
In HT29 cells, the maximum percentage of MTX-trea-
ted cells undergoing apoptosis was 28% while it was 20%
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Page 6 of 12in untreated cells. The highest level of cell apoptosis was
maximal 6 hr after MTX withdrawal (Figure 6C).
Discussion
The objective of this work was to improve the efficiency
of retroviral transfer of the suicide gene HSV-tk in
colon cancer cells. This aim was achieved through the
pharmacological control of the target cells cell cycle.
Our results are consistent with previous reports showing
that retroviral-mediated gene transfer depends on the
cell cycle of target cells. The nuclear transfer of the pre-
integrative viral complex is a strong limit to the effi-
ciency of defective amphotrophic retroviral vectors
derived from murine leukemia virus (MuLV). This step
i sp o s s i b l eo n l yt h r o u g ht h em e t a p h a s i cb r e a k d o w no f
the nuclear membrane [14,16,30]. Therefore, the inte-
gration of retroviral DNA during cell division has only
been evidenced when the doubling time of target cells
A
B
Figure 3 Detection of HSV-TK protein.D H D K 1 2c e l l s( A) and DHDK12 cells transduced with the HSV-tk retroviral vector (B)w e r e
immunostained for HSV-TK. Cells seeded on chamber were transduced with TG 9344. After 48 hr, cells were fixed with 4% paraformaldehyde
and stained with a mouse monoclonal 4C8 antibody against HSV-TK protein.
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Page 8 of 12was higher than the half-life of the virus [15]. As the
half-life of MuLV-derived vectors is between 5.5 and 7.5
hr [31] and as the DHDK12 and HT29 cell lines have a
doubling time of 28 hr [32] and 24 hr [33], respectively,
our model meet this criterion. Our experimental design
thus was adapted to study the efficiency of retroviral
gene transfer after pharmacological control of the cell
cycle.
Cell synchronization has been used to increase the
number of cells accessible to drug targeting DNA and
to improve the action of several anti-proliferative che-
motherapies [20,23,24]. In this regard, experimental
works have studied the synchronization in S phase of
cancer cell lines by MTX, aphidicolin or ara-C. Aphidi-
colin and ara-C are reversible inhibitors of DNA poly-
merases [18,22]. MTX induces a reversible inhibition of
dihydrofolate reductase, which is required for the de
novo synthesis of nucleotides for DNA replication [34].
Our study showed a limited efficiency of ara-C or aphi-
dicolin in DHDK12 cells. Moreover, a significant toxicity
of aphidicolin, not compatible with an in vivo applica-
tion, has been observed on several cancer cell lines
[19,35]. We observed that non-toxic concentrations of
MTX induced a reversible synchronization of DHDK12
and HT29 cells in early S phase (Figure 1). A 24 hr-
treatment with MTX allowed increasing the rate of cells
622 bp
527 bp
404 bp
307 bp
242 bp
12 3 4 5 6 7
Figure 5 Internucleosomal DNA fragmentation induced by GCV. Lane 1 and lane 4 show DHDK12 cells and HT29 cells transduced with TG
9344 and treated for 96 hr with 20 μM GCV, respectively. Lane 3 and 5 show DHDK12 cells and HT29 cells transduced with TG 9344 after a 24
hr pretreatment with MTX and treated for 96 hr with 20 μM GCV, respectively. Lane 6 and 7 show DHDK12 cells and HT29 cells treated for 24 h
with MTX, respectively. Lane 2 shows pBR 322 base pair size markers. Qualitative detection of DNA was achieved by ethidium bromide staining.
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Page 9 of 12in S phase. The reversibility of MTX was confirmed as
the cells returned to the normal cell cycle according to
there doubling time. These results were in accordance
to those obtained in others cell lines [36].
The reverse transcription of retroviral DNA can occur
in several phases of the cell cycle [16]. However, the
cells should be stimulated to divide before infection for
efficient gene transfer [37]. According to the intracellu-
lar half-life of retroviral intermediates, the position of
target cells relative to mitosis and the duration of S
phase at the time of exposure both are critical to deter-
mine the efficiency of infection [38]. This assumption
was supported by the difference in retroviral gene trans-
fer improvement between DHDK12 and HT29 cell lines
after cell synchronization by MTX. These two colon
cancer cell lines exhibit a different pattern of cell cycle
distribution after synchronization (Figure 1). We have
observed that in HT29 cells the level of transgene
expression, which was lower than that observed in
DHDK12 cells, was strictly related to the peak of cells in
S phase (Figure 2B). In DHDK12 cell line, the peak of
cells in S phase was located 10 hr after the recovery and
the infection efficiency was improved by 2-fold 20 hr
after MTX removal (Figure 2A). The time difference
between the maximum level of DHDK12 cells in S
phase and the maximum efficiency of transduction
could be related to the reverse transcription and integra-
tion of the viral DNA. Thus, the period of internaliza-
tion and reverse transcription, which lasts 4 to 8 hours
[16], must correspond to the interval necessary for cells
synchronized in S phase to reach the G2-M phase to
obtain the optimal integration of viral DNA. Our results
indicate that the pattern of synchronization in DHDK12
cells at 20 hr after MTX removal is adapted to these
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Figure 6 Induction of apoptosis. Untransduced DHDK12 cells (A) were treated with MTX, GCV or the combination of MTX plus GCV for 24 h.
Transduced DHDK12 cells (B) and transduced HT29 cells (C) were treated for 24 hr with (filled square) or without (open square) MTX. Cells were
transduced with TG 9344 at the indicated times after MTX washout and 48 hr after transduction were treated with 20 μM GCV for 72 hr.
Quantitative detection of apoptosis was determined by biparametric flow cytometry analysis of fluorescein labeled-annexin V cells and PI.
Apoptotic cells were annexin V positive, PI negative. Data are expressed as the mean ± SE from at least three separate experiments. * P <.05 vs
untreated cells
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Page 10 of 12criteria. In contrast to DHDK12 cells, HT29 cells syn-
chronized in S phase reach more rapidly the G2-M
phase, which may prevent optimal internalization and
reverse transcription of the viral DNA in HT29 cells.
This hypothesis is consistent with a model analyzing the
kinetic of short half-life retrovirus mediated gene trans-
fer [17]. Taken together, this allows delineating an opti-
mal period for the retroviral gene transfer in
synchronized target cells.
Quantitative detection of GCV-induced apoptosis was
used to determine whether the increased efficiency of
the HSV-tk retroviral gene transfer resulted in an
increase in GCV-mediated cell death. The transduction
rate of HSV-tk gene reached 30% in the DHDK12 cell
line 20 hr after MTX removal, doubling the efficiency of
retroviral gene transfer observed in untreated cells.
Although the transduction rates of the b-gal reporter
gene or the HSV-tk gene may appear rather low, they
constitute a two-fold increase compared with the trans-
duction rates previously described [12,13]. Indeed, in the
aforementioned studies, the fraction of infected cells was
less than 10% whereas in our experimental design it
reached 30% in the DHDK12 cell line 20 hr after MTX
removal. Because Chen et al. [9] have previously
demonstrated that a higher level of HSV-TK expression
correlates with greater bystander effect leading to
increased cell killing, the increased transduction rate
that we reached in our study could enhance GCV-
mediated cell death. Consistently, our results show that
the number of cells in apoptosis was higher than the
number of cells expressing HSV-TK indicating greater
bystander effect. Altogether, these observations indicate
that improvement of transduction efficiency may repre-
sent a key step in retroviral suicide gene therapy by
increasing both suicide gene expression and bystander
effect.
We acknowledge nevertheless that this study has some
limitations. Indeed, MTX was less efficient in HT29
cells than in DHDK12 cells in improving retroviral gene
transfer and subsequently cell apoptosis after GCV
treatment. This could be explained by an adverse effect
of MTX metabolization leading to the inhibition of ret-
roviral cycle. Indeed, the MTX metabolites have been
shown to inhibit retroviral infection [39]. However, the
rate of HT29 transduced cells undergoing apoptosis
after GCV treatment increased from 20% to 28% in cells
pre-treated with MTX. We are currently investigating
whether a rescue strategy could antagonize the inhibi-
tory effect of MTX metabolites on retroviral infection.
Conclusions
We show here that cell synchronization may improve
the efficacy of retroviral suicide gene transfer in a
human and a murine colon cancer cell lines. Because
the effect of cell synchronization on retroviral gene
transfer differs between the two colon cancer cell lines
used in this study, further investigations in more colon
cancer cell lines are needed to draw definitive conclu-
sion on the improvement of retroviral gene transfer
after cell synchronization. Nevertheless, we demonstrate
in the present study that this improvement increases the
level of apoptosis induced with GCV treatment. This
approach could be fruitful in colon cancer liver metas-
tases because tumor cells are proliferating in a quiescent
parenchyma. Therefore, we are currently assessing in a
rat model of liver tumors whether this strategy could
improve the antitumoral efficacy of cancer gene therapy
using defective retroviral vectors.
Additional material
Additional file 1: Ara-C and Aphidicolin mediated effects on
DHDK12 cell cycle. DHDK12 cells were treated with 0.075 μM ara-C or
25 μ M aphidicolin for 24 h. The percentage of cells in S phase (open
square: aphidicolin; filled square: ara-C) and in G1 phase (open triangle:
aphidicolin; filled triangle: ara-C) at various time after ara-C or aphidicolin
removal was determined by flow cytometry analysis of DNA content
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